image
Healthcare - Medical - Devices - NASDAQ - US
$ 12.96
-0.0771 %
$ 337 M
Market Cap
-4.89
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one CVRX stock under the worst case scenario is HIDDEN Compared to the current market price of 13 USD, CVRx, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one CVRX stock under the base case scenario is HIDDEN Compared to the current market price of 13 USD, CVRx, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one CVRX stock under the best case scenario is HIDDEN Compared to the current market price of 13 USD, CVRx, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
51.3 M REVENUE
30.53%
-59.5 M OPERATING INCOME
-38.02%
-60 M NET INCOME
-45.55%
-39.1 M OPERATING CASH FLOW
-0.32%
-1.36 M INVESTING CASH FLOW
-130.29%
55.9 M FINANCING CASH FLOW
132.95%
15.3 M REVENUE
14.72%
-10.3 M OPERATING INCOME
21.04%
-10.7 M NET INCOME
18.69%
-8.01 M OPERATING CASH FLOW
23.07%
-52 K INVESTING CASH FLOW
-40.54%
13.8 M FINANCING CASH FLOW
-65.59%
Balance Sheet CVRx, Inc.
image
Current Assets 130 M
Cash & Short-Term Investments 106 M
Receivables 9.27 M
Other Current Assets 14.6 M
Non-Current Assets 3.6 M
Long-Term Investments 0
PP&E 3.57 M
Other Non-Current Assets 27 K
Current Liabilities 10.8 M
Accounts Payable 2.58 M
Short-Term Debt 0
Other Current Liabilities 8.18 M
Non-Current Liabilities 51.6 M
Long-Term Debt 50.2 M
Other Non-Current Liabilities 1.45 M
EFFICIENCY
Earnings Waterfall CVRx, Inc.
image
Revenue 51.3 M
Cost Of Revenue 8.33 M
Gross Profit 43 M
Operating Expenses 102 M
Operating Income -59.5 M
Other Expenses 475 K
Net Income -60 M
RATIOS
83.75% GROSS MARGIN
83.75%
-115.98% OPERATING MARGIN
-115.98%
-116.91% NET MARGIN
-116.91%
-84.39% ROE
-84.39%
-44.95% ROA
-44.95%
-48.55% ROIC
-48.55%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis CVRx, Inc.
image
Net Income -60 M
Depreciation & Amortization 619 K
Capital Expenditures -1.36 M
Stock-Based Compensation 19 M
Change in Working Capital 949 K
Others 3.3 M
Free Cash Flow -40.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets CVRx, Inc.
image
Wall Street analysts predict an average 1-year price target for CVRX of $15.9 , with forecasts ranging from a low of $12 to a high of $23 .
CVRX Lowest Price Target Wall Street Target
12 USD -7.41%
CVRX Average Price Target Wall Street Target
15.9 USD 22.35%
CVRX Highest Price Target Wall Street Target
23 USD 77.47%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership CVRx, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
19.4 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
323 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 months ago
Nov 19, 2024
Sell 19.4 K USD
VERRASTRO PAUL
CHIEF MKTG & STRAT OFFICER
- 1430
13.5781 USD
6 months ago
Aug 15, 2024
Bought 24.3 K USD
SLATTERY JOSEPH P
Director
+ 3000
8.1 USD
6 months ago
Aug 08, 2024
Bought 24.7 K USD
SLATTERY JOSEPH P
Director
+ 3000
8.2386 USD
6 months ago
Aug 06, 2024
Bought 22.7 K USD
SLATTERY JOSEPH P
Director
+ 2500
9.09 USD
6 months ago
Aug 05, 2024
Bought 251 K USD
Hykes Kevin
PRES & CEO
+ 30000
8.3589 USD
1 year ago
Feb 16, 2024
Sell 96.1 K USD
JOHNSON & JOHNSON
10 percent owner
- 3725
25.81 USD
1 year ago
Feb 20, 2024
Sell 55.7 K USD
VERRASTRO PAUL
CHIEF MKTG & STRAT OFFICER
- 2545
21.905 USD
1 year ago
Aug 03, 2023
Sell 11.7 K USD
VERRASTRO PAUL
CHIEF MKTG & STRAT OFFICER
- 628
18.5549 USD
1 year ago
Jul 31, 2023
Sell 19.6 K USD
VERRASTRO PAUL
CHIEF MKTG & STRAT OFFICER
- 1122
17.4948 USD
2 years ago
Nov 28, 2022
Sell 47.4 K USD
VERRASTRO PAUL
director: CHIEF MKTG & STRAT OFFICER
- 4000
11.8545 USD
2 years ago
Nov 28, 2022
Sell 7.51 K USD
VERRASTRO PAUL
director: CHIEF MKTG & STRAT OFFICER
- 600
12.5217 USD
2 years ago
May 24, 2022
Bought 40.8 K USD
Nielsen Kirk G.
director:
+ 8070
5.0498 USD
2 years ago
May 23, 2022
Bought 22.3 K USD
Nielsen Kirk G.
Director
+ 4432
5.0396 USD
2 years ago
May 20, 2022
Bought 67.4 K USD
Nielsen Kirk G.
Director
+ 13387
5.0354 USD
2 years ago
May 19, 2022
Bought 55.3 K USD
Nielsen Kirk G.
director:
+ 10976
5.038 USD
2 years ago
May 03, 2022
Bought 23.9 K USD
Nielsen Kirk G.
director:
+ 3992
5.996 USD
2 years ago
May 04, 2022
Bought 153 K USD
Nielsen Kirk G.
Director
+ 25503
5.9899 USD
2 years ago
May 03, 2022
Bought 197 K USD
Nielsen Kirk G.
Director
+ 32809
5.9972 USD
2 years ago
Apr 28, 2022
Bought 251 K USD
Nielsen Kirk G.
director:
+ 41988
5.9701 USD
2 years ago
Apr 28, 2022
Bought 597 USD
Nielsen Kirk G.
Director
+ 100
5.97 USD
3 years ago
Feb 28, 2022
Bought 5.42 K USD
Jain Mudit K.
Director
+ 600
9.0327 USD
3 years ago
Feb 24, 2022
Bought 28 K USD
Nielsen Kirk G.
Director
+ 3400
8.2381 USD
3 years ago
Feb 23, 2022
Bought 307 K USD
Nielsen Kirk G.
Director
+ 38200
8.0404 USD
3 years ago
Feb 22, 2022
Bought 318 K USD
Nielsen Kirk G.
Director
+ 40008
7.9399 USD
3 years ago
Feb 18, 2022
Bought 211 K USD
Nielsen Kirk G.
Director
+ 26659
7.9233 USD
3 years ago
Nov 19, 2021
Bought 4.11 K USD
Jain Mudit K.
Director
+ 300
13.6875 USD
3 years ago
Nov 18, 2021
Bought 12.8 K USD
Jain Mudit K.
Director
+ 875
14.6327 USD
3 years ago
Aug 12, 2021
Bought 12.3 K USD
Jain Mudit K.
Director
+ 625
19.7248 USD
3 years ago
Jul 02, 2021
Bought 4.06 M USD
NEA PARTNERS 10 L P
10 percent owner
+ 225500
18 USD
3 years ago
Jul 02, 2021
Bought 446 K USD
NEA PARTNERS 10 L P
10 percent owner
+ 24750
18 USD
3 years ago
Jul 02, 2021
Bought 4.06 M USD
NEW ENTERPRISE ASSOCIATES 10 L P
10 percent owner
+ 225500
18 USD
3 years ago
Jul 02, 2021
Bought 4.95 M USD
GLAXOSMITHKLINE PLC
10 percent owner
+ 275000
18 USD
3 years ago
Jul 02, 2021
Bought 500 K USD
NEHRA JOHN M
Director
+ 27777
18 USD
3 years ago
Jul 01, 2021
Bought 1.29 K USD
NEHRA JOHN M
Director
+ 50
25.8 USD
3 years ago
Jun 30, 2021
Bought 1.37 K USD
NEHRA JOHN M
Director
+ 50
27.4257 USD
3 years ago
Jul 02, 2021
Bought 4 M USD
Jain Mudit K.
Director
+ 222222
18 USD
3 years ago
Jul 01, 2021
Bought 25.1 K USD
Jain Mudit K.
Director
+ 1000
25.1 USD
3 years ago
Jul 02, 2021
Bought 4.95 M USD
Pardo Geoffrey B
Director
+ 275000
18 USD
7. News
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction globenewswire.com - 2 weeks ago
CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? CVRx (CVRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com - 2 weeks ago
Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in CVRx (CVRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 3 weeks ago
CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript CVRx, Inc. (NASDAQ:CVRX ) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Mike Vallie - Investor Relations, ICR Healthcare Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Macauley Kilbane - William Blair William Plovanic - Canaccord Genuity Samantha Munoz - Piper Sandler Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the CVRx Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 3 weeks ago
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates CVRx (CVRX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.44 per share a year ago. zacks.com - 3 weeks ago
CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2024. globenewswire.com - 3 weeks ago
CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025 MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. globenewswire.com - 1 month ago
CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy? CVRx (CVRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 month ago
CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast. globenewswire.com - 2 months ago
CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast. globenewswire.com - 3 months ago
CVRx: Impressive Top-Line Growth Seems Priced In CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution. seekingalpha.com - 3 months ago
CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript CVRx, Inc. (NASDAQ:CVRX ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Mike Vallie - Investor Relations Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Macauley Kilbane - William Blair Rohin Patel - JPMorgan Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald. Operator Welcome to CVRx Q3 2024 Earnings Call. seekingalpha.com - 4 months ago
8. Profile Summary

CVRx, Inc. CVRX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 337 M
Dividend Yield 0.00%
Description CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Contact 9201 West Broadway Avenue, Minneapolis, MN, 55445 https://www.cvrx.com
IPO Date June 30, 2021
Employees 206
Officers Mr. Robert Allen John Chief Revenue Officer Ms. Jonelle R. Burnham Vice President & General Counsel Mr. Paul Pignato Vice President of Research, Development and Operations Dr. Philip B. Adamson M.D., M.Sc. Chief Medical Officer Mr. Kevin Hykes President, Chief Executive Officer & Director Ms. Bonnie Handke M.B.A., R.N. Senior Vice President of Patient Access, Reimbursement, & Healthcare Economics